All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Novel Agents Continue to Transform Lymphoma Treatment

July 27th 2015

Gilles A. Salles, MD, PhD, discussed treatment regimens being developed for follicular lymphoma.

FDA Expands Carfilzomib's Myeloma Approval

July 24th 2015

The FDA has broadened the approval of carfilzomib to include patients with relapsed multiple myeloma who have received at least one prior therapy.

FDA Approves Sonidegib for Basal Cell Carcinoma

July 24th 2015

The FDA has approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred.

Efficacy Maintained, QoL Improved With Radiation Dose Reductions in Oropharyngeal Cancer

July 24th 2015

Barbara Ann Burtness, MD, discusses the impact of two studies examining reductions in radiation and chemotherapy dose in low-risk HPV-associated oropharyngeal cancer.

Pembrolizumab Benefit in SCCHN Confirmed in Expansion Study

July 24th 2015

Tanguy Y. Seiwert, MD, discusses the significance of the expansion results of KEYNOTE-012 for advanced squamous cell carcinoma of the head and neck.

Regulatory Filings Move Dabrafenib/Trametinib Combo Closer to Full Melanoma Approval

July 24th 2015

The FDA has assigned a priority review designation to the combination of dabrafenib and trametinib for patients with unresectable or metastatic BRAFV600 mutation-positive melanoma.

Cancer Care Leaders Demand Drug Pricing Reforms

July 23rd 2015

A slate of 118 well-known cancer experts have signed their names to a list of recommended drug pricing reforms in hopes of curbing the soaring costs of cancer care and spurring a grassroots movement to combat the trend.

FDA Approval Sought for Maintenance Ofatumumab in CLL

July 23rd 2015

A supplemental biologics license application has been submitted to the FDA for ofatumumab as a maintenance therapy in patients with relapsed chronic lymphocytic leukemia following a response to second- or third-line therapy.

Carfilzomib ENDEAVOR Data Submitted to FDA for Myeloma Approval

July 23rd 2015

A supplemental new drug application has been submitted for carfilzomib (Kyprolis) in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

OncLive® Expands its Roster of Strategic Alliance Partners With Sylvester Comprehensive Cancer Center

July 23rd 2015

OncLive  editorial, marketing teams will share news about Sylvester Center.

Dabrafenib/Trametinib Combo Receives Breakthrough Designation for NSCLC

July 23rd 2015

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib as a potential treatment for patients with BRAFV600E-mutant non-small cell lung cancer.

Failure to Follow Weight-Based Chemo Guidelines Lowers Survival in Ovarian Cancer

July 23rd 2015

Women with ovarian cancer who experienced an average dose reduction of ≤85% had a 35% higher mortality risk than those who received normal dosing.

Selumetinib Misses Endpoint in Phase III Uveal Melanoma Study

July 22nd 2015

Treatment with the combination of selumetinib and dacarbazine failed to improve progression-free survival compared with dacarbazine alone in patients with metastatic uveal melanoma.

Progress in HER2-Positive Breast Cancer Comes With Successes and Setbacks

July 22nd 2015

Mohammad Jahanzeb, MD, discusses impactful studies and other key issues in HER2-positive breast cancer.

European Commission Approves Pembrolizumab for Advanced Melanoma

July 22nd 2015

The European Commission has approved the PD-1 inhibitor pembrolizumab as a treatment for adult patients with unresectable or metastatic melanoma in the first-line and previously treated settings.

Court Clears First US Biosimilar for Future Marketing

July 21st 2015

An appellate court ruled that the FDA-approved biosimilar Zarxio can be marketed in the United States after September 2, 2015.

Efforts Continue to Refine Neoadjuvant HER2+ Breast Cancer Care

July 21st 2015

Douglas Yee, MD, explains current treatment options and ongoing research aimed at optimizing neoadjuvant therapy for HER2-positive breast cancer.

Nivolumab Gains European Approval for Squamous NSCLC

July 20th 2015

The European Commission has approved nivolumab as a treatment for patients with locally advanced or metastatic squamous non–small cell lung cancer following prior chemotherapy.

Nivolumab Improves Survival in Phase III RCC Trial

July 20th 2015

The phase III CheckMate-025 trial has been halted after an independent panel determined that nivolumab improved overall survival versus everolimus in patients with advanced renal cell carcinoma.

Second-Line Cabozantinib Improves OS, PFS in mRCC

July 20th 2015

Treatment with cabozantinib improved progression-free survival and overall survival compared with everolimus in pretreated patients with metastatic renal cell carcinoma.

x